Probing pediatric pigmented purpuras
By Warren R. Heymann, MD, FAAD
October 20, 2021
Vol. 3, No. 42
Pigmented purpuric (PP) eruptions are often referred to as “benign” pigmented purpuras. Although that may be true in the medical sense, these dermatoses may be very distressing for patients (or their parents). Angst may be due to any (or all) of the following: confirming the diagnosis, concern for systemic disease until a diagnosis is rendered, an unpredictable prognosis, a relative lack of effective therapy, and the cosmetic appearance.
PPs are classically considered as one of 5 types: Schamberg disease (progressive pigmentary dermatosis); pigmented purpuric lichenoid dermatosis of Gougerot‐Blum; purpura annularis telangiectodes (Majocchi disease); lichen aureus, and the eczematoid‐like purpura of Doucas and Kapetanakis. A sixth type, a granulomatous pigmented purpuric dermatosis, often associated with hyperlipidemia, has been recently described. (1)
Biopsies and/or appropriate serologic studies should be considered when there are other diagnostic considerations such as leukocytoclastic vasculitis, cutaneous T-cell lymphoma, hypergammaglobulinemic purpura of Waldenström, or cryoglobulinemia.
The etiology of PPs is unknown (“idiopathic”). Histologically, it is considered a lymphocytic capillaritis, with a perivascular T-cell infiltrate, extravasated erythrocytes, and hemosiderin. Reported aggravating factors include hypertension, diabetes, gravitational dependency, venous stasis, capillary fragility, infections (hepatitis B), drugs (aspirin, acetaminophen, amlodipine, glipizide, and others), and presumed immunodysregulation. (2) Rare familial cases have been reported, suggesting genetic influence, as first described by Baden in a 51-year-old man and his 17-year-old son. (3)
This commentary will focus on pediatric PP eruptions.
Coulombe et al retrospectively reviewed their experience with 17 patients with biopsy-proven PPs; 8 were male and the mean age of onset was 9 years. PP was asymptomatic in 11 patients, pruritic in 3, and of cosmetic concern in 3. Schamberg’s disease was the most frequent subtype in 12 cases. Resolution of PP was found in 13 cases with a median duration of less than 1 year (range 6 months-9 years). Five patients experienced spontaneous clearing without treatment, and improvement was observed in 75% of cases treated with topical corticosteroids and 100% with narrowband ultraviolet B (nbUVB). No associated diseases, significant drug exposure, or contact allergens were found. These findings support that PPs in children are idiopathic, chronic eruptions that can benefit from watchful waiting, although topical corticosteroids or nbUVB may be useful if the patient or family desires faster resolution. The authors acknowledge that their study was limited by its small size, its retrospective nature, and selection and recall bias. (4)
Plachouri et al reviewed therapeutic strategies for PPs, noting that no evidence-based treatments have been found to be dramatically effective for most patients. Most reports are case studies or small case series — the need for prospective studies is readily apparent. Local therapies include compression, topical steroids, and calcineurin inhibitors. Systemic treatments include the flavonoid rutoside, vitamin C, colchicine, pentoxifylline, griseofulvin, systemic steroids, cyclosporine, and methotrexate. Ultraviolet light (nbUVB and PUVA), lasers (1540 nm erbium, 595 pulsed dye), and intense pulsed light combined with photodynamic therapy have all been reported to be beneficial to some degree. (5) I cannot think of another condition where primum non nocere (first do no harm) is more apropos.
Ollech et al performed a retrospective study of the clinical course and utility of vitamin C and rutoside in children with PPs treated at their institution between 2008 and 2018. A total of 101 patients were evaluated. The female : male ratio was 1.3 : 1, and the median age at diagnosis was 8.8 years. Median follow-up was 7.13 months. The most common PP subtypes were lichen aureus (43%) and Schamberg (34%). Fifty-three (52%) patients had evaluable follow-up documentation via their medical record or phone questionnaire. Twenty-eight patients were treated with vitamin C or rutoside or combination therapy. Twenty-five patients received no treatment. Clearance of the rash was noted in 24 (45.3%) patients overall, including 10 (42%) patients in the treated group and 14 (58%) patients in the untreated group. Recurrence was noted in seven (13.2%) patients. One patient with biopsy-proven linear PP evolved into linear morphea several months following clearance of the PP. Treatment with vitamin C and/or rutoside was well tolerated without side effects. None of the patients were subsequently diagnosed with vasculitis, coagulopathy or cutaneous T-cell lymphoma. The authors concluded that PPs in children are benign dermatoses with high rates of complete resolution. Although treatment with vitamin C and rutoside is well tolerated, there did not appear to be an advantage over watchful waiting without therapy. (6)
Jay Frank Schamberg first described progressive pigmentary dermatosis in 1901. I have a copy of the sixth edition of his textbook published in 1921. He states the following about treating purpura: “The treatment of purpura must be adapted to the exigencies of the individual case. Ergot, tincture of the chlorid of iron, quinin, turpentine, and the mineral acids are useful in all forms of the disease.” (7) A century later, the first sentence remains relevant.
Point to Remember: Pigmented purpuric eruptions may be seen in the pediatric population. Although many approaches have been reported as beneficial, these are based on small case reports and series. Tincture of time (watchful waiting) may be a reasonable approach for many patients.
Our expert’s viewpoint
Albert C. Yan, MD
Professor of Pediatrics and Dermatology
Perelman School of Medicine, University of Pennsylvania
When I was a Penn resident working with Dr. Jim Leyden, I recall him observing, half-facetiously, that you might want to “hurry up and treat” a particular patient, the implication being that whatever you use will appear effective in a condition that spontaneously remits.
So I am gratified to read this article which highlights the generally benign nature of pediatric pigmented purpuric dermatosis. I have encountered several dozen children with PPD over the years and have been impressed with how some spontaneously resolve while others are resistant to many attempted treatments only to later resolve. This article nicely shows that at least in this retrospective series, not treating — active non-intervention — was as successful as active intervention. Sometimes the best treatment is no treatment at all.
García-Rodiño S, Rodríguez-Granados MT, Seoane-Pose MJ, Espasandín-Arias M, Barbeito-Castiñeiras G, Suárez-Peñaranda JM, Vázquez-Veiga H. Granulomatous variant of pigmented purpuric dermatosis: report of two cases and review of the literature. J Dtsch Dermatol Ges. 2017 May;15(5):565-569.
Zaldivar Fujigaki JL, Anjum F. Schamberg Disease. 2020 Aug 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan.
Baden HP. Familial Schamberg’s disease. Arch Dermatol. 1964 Oct;90:400.
Coulombe J, Jean SE, Hatami A, Powell J, Marcoux D, Kokta V, McCuaig C. Pigmented purpuric dermatosis: clinicopathologic characterization in a pediatric series. Pediatr Dermatol. 2015 May-Jun;32(3):358-62.
Plachouri KM, Florou V, Georgiou S. Therapeutic strategies for pigmented purpuric dermatoses: a systematic literature review. J Dermatolog Treat. 2019 Mar;30(2):105-109.
Ollech A, Paller AS, Kruse L, Kenner-Bell B, Chamlin S, Wagner A, Shen L, Yousif R, Balmert LC, Mancini AJ. Pigmented purpuric dermatosis in children: a retrospective cohort with emphasis on treatment and outcomes. J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2402-2408.
Schamberg JF. Purpura simplex. In A Compend of Diseases of the Skin. P. Blakiston’s Son & Co. Philadelphia, 1921, pp 166-168.
All content found on Dermatology World Insights and Inquiries, including: text, images, video, audio, or other formats, were created for informational purposes only. The content represents the opinions of the authors and should not be interpreted as the official AAD position on any topic addressed. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
DW Insights and Inquiries archive
Explore hundreds of Dermatology World Insights and Inquiries articles by clinical area, specific condition, or medical journal source.
All content solely developed by the American Academy of Dermatology
The American Academy of Dermatology gratefully acknowledges the support from Incyte Dermatology.